CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming
Ling Tao1,2, Myrthala Moreno-Smith1,2, Rodrigo Ibarra-García-Padilla3
1Department of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX, 77030, USA.
Abstract:
Neuroblastoma (NB) arises from oncogenic disruption of neural crest (NC) differentiation. Treatment with retinoic acid (RA) to induce differentiation has improved survival in some NB patients, but not all patients respond, and most NBs eventually develop resistance to RA. Loss of the chromatin modifier chromatin assembly factor 1 subunit p150 (CHAF1A) promotes NB cell differentiation; however, the mechanism by which CHAF1A drives NB oncogenesis has remained unexplored. This study shows that CHAF1A gain-of-function supports cell malignancy, blocks neuronal differentiation in three models (zebrafish NC, human NC, and human NB), and promotes NB oncogenesis. Mechanistically, CHAF1A upregulates polyamine metabolism, which blocks neuronal differentiation and promotes cell cycle progression. Targeting polyamine synthesis promotes NB differentiation and enhances the anti-tumor activity of RA. The authors' results provide insight into the mechanisms that drive NB oncogenesis and suggest a rapidly translatable therapeutic approach (DFMO plus RA) to enhance the clinical efficacy of differentiation therapy in NB patients.
Insights
Chromatin assembly factor 1 subunit p150 (CHAF1A) drives neuroblastoma (NB) oncogenesis by blocking neuronal differentiation via polyamine metabolism. Targeting polyamine synthesis with DFMO enhances retinoic acid (RA) therapy efficacy in NB.
Area of Science:
- Oncology
- Developmental Biology
- Molecular Biology
Background:
- Neuroblastoma (NB) is driven by oncogenic disruption of neural crest (NC) differentiation.
- Retinoic acid (RA) therapy improves survival in some NB patients, but resistance and lack of response are significant challenges.
- The role of chromatin assembly factor 1 subunit p150 (CHAF1A) in NB oncogenesis and its mechanism were previously unexplored.
Purpose of the Study:
- To investigate the mechanism by which CHAF1A promotes neuroblastoma (NB) oncogenesis.
- To determine if CHAF1A gain-of-function affects neuronal differentiation and cell malignancy.
- To explore therapeutic strategies targeting CHAF1A-mediated pathways to enhance NB differentiation therapy.
Main Methods:
- Utilized zebrafish NC, human NC, and human NB cell models.
- Assessed the impact of CHAF1A gain-of-function on neuronal differentiation and cell cycle progression.
- Investigated the role of polyamine metabolism in CHAF1A-driven oncogenesis.
- Evaluated the efficacy of targeting polyamine synthesis (e.g., DFMO) in combination with RA.
Main Results:
- CHAF1A gain-of-function supports cell malignancy and blocks neuronal differentiation across multiple models.
- CHAF1A upregulates polyamine metabolism, inhibiting neuronal differentiation and promoting cell cycle progression.
- Targeting polyamine synthesis with DFMO effectively promotes NB differentiation.
- Combining DFMO with RA enhances anti-tumor activity and improves differentiation therapy efficacy.
Conclusions:
- CHAF1A is a key driver of neuroblastoma (NB) oncogenesis by suppressing neuronal differentiation through polyamine metabolism.
- Upregulation of polyamine metabolism by CHAF1A is a critical mechanism in NB development.
- Targeting polyamine synthesis, particularly with DFMO in combination with RA, represents a promising therapeutic strategy to overcome RA resistance and improve NB treatment outcomes.
Related Concept Videos
02:23Abnormal Proliferation
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...